Organisation paid for research Program year 2024 Source: CMS Open Payments

Albemarle Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$164,090

104 payments

Through program year 2024, Albemarle Clinical Trials LLC is reported as receiving $164,090 in research payments, across 104 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $13,523 1
2023 Research $22,113 5
2022 Research $26,007 9
2021 Research $24,618 8
2020 Research $29,129 33
2019 Research $48,700 48

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $95,547 76 payments
  2. AbbVie, Inc. $58,609 13 payments
  3. Alcon Research LLC $9,934 15 payments
Studies the money was for Research payments · program years 2019–2024
  1. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $44,993 11 payments
  2. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $26,175 8 payments
  3. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $23,916 26 payments
  4. The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $20,536 12 payments
  5. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $14,387 16 payments
  6. 1698-302-007 Ph3 Extension Study (M21-489) $13,523 1 payment
  7. US Confirmatory Trial of Clareon IOL ( Clareon - UltraSert and Wagon Wheel) $9,934 15 payments
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $5,340 1 payment
  9. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patient with Open Angle Glaucoma or Ocular Hypertension $2,189 8 payments
  10. A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features $1,830 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record